Holen Sie sich die Stockscreener-App
6.96
4.53%
-0.33
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences - Yahoo Finance
Operating income of Ocular Therapeutix Inc – HAN:0OT - TradingView
RBC Capital reiterates Ocular Therapeutix stock rating on wAMD treatment potential - Investing.com Nigeria
ETFs Investing in Ocular Therapeutix Inc Stocks - TradingView
OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights - Stocktwits
Precision Trading with Ocular Therapeutix Inc. (OCUL) Risk Zones - Stock Traders Daily
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
Ocular Therapeutix, Inc. (OCUL) Stock Price, News, Quote & History - ca.finance.yahoo.com
Ocular Therapeutix (OCUL) Dropped, So What Is Behind The Latest Attention? - Simply Wall Street
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst? - AlphaStreet
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success - TradingView
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring a 171% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment - HCPLive
Ocular Therapeutix, Inc.Common Stock (NQ: OCUL - The Chronicle-Journal
New Ocular Therapeutix Target Price Amid Support - TheStreet Pro
Nine new hires receive stock awards at Ocular Therapeutix - Stock Titan
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI - Glance by Eyes On Eyecare
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com
HC Wainwright & Co. reiterates Buy rating on Ocular Therapeutix, $25 price target - TradingView
Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI By Investing.com - Investing.com Nigeria
Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4 - marketscreener.com
Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI - Investing.com
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD - Stock Titan
Ocular Therapeutix (OCUL) Up 5.8% to $11.26, Testing Key Resistance at $11.82Insider Buying Alerts - careplusvn.com
OCUL News | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs - Yahoo Finance
Ocular Therapeutix (OCUL) COO sells shares to cover taxes - Stock Titan
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ocular Therapeutix (NASDAQ: OCUL) holder to sell 1,099 shares - Stock Titan
This Insider Has Just Sold Shares In Ocular Therapeutix - webull.com
Ocular Therapeutix Inc. (OCUL) Peer Comparison – Compare with Others - Value Research
Ocular Therapeutix CDO Peter Kaiser sells $32,686 of OCUL shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CEO Dugel sells $233,159 in shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CSO Heier sells $35,530 in stock - Investing.com
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares - Investing.com
Ocular Therapeutix CDO Peter Kaiser sells $32,686 of OCUL shares - Investing.com
Ocular Therapeutix (NASDAQ: OCUL) exec share sale covers RSU tax withholding - Stock Titan
Ocular Therapeutix CEO Dugel sells $233,159 in shares - Investing.com
Ocular Therapeutix (NASDAQ: OCUL) officer to sell 1,897 shares - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) insider plans 21,649-share sale - stocktitan.net
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update - Yahoo Finance
META_TITLE_QUOTE - Yahoo Finance
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular (OCUL) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Latest Session; Market Reaction: The Stock Ends Down 5.46% in the Available RecordPost-Announcement Reaction - vinanet.vn
Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the DayAdjusted Earnings Analysis - vinanet.vn
Ocular Therapeutix (OCUL) Institutional Ownership 2026 - MarketBeat
Clear Street Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Why Is Ocular Therapeutix Stock Gaining Monday? - Sahm
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):